Deliberazione
Autorizzazione allo studio clinico osservazionale, farmacologico, profit, denominato: “ASTER:Anifrolumab Study for Treatment Effectiveness in the Real World Multi-National, Observational, Post-Launch Effectiveness Study Among SLE Patients Receiving Anifrolumab in Routine Clinical Practice” - Codice Protocollo D3461R00043
N° 619
del 09/11/2023
